TISIDB

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Nucleus, nucleolus. Cytoplasm Note=Isoforms lacking the KTS motif have a diffuse nuclear location (PubMed:15520190). Shuttles between nucleus and cytoplasm. ; SUBCELLULAR LOCATION: Isoform 1: Nucleus speckle ; SUBCELLULAR LOCATION: Isoform 4: Nucleus, nucleoplasm
Domain	PF02165 Wilm's tumour protein
Function	Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1 has lower affinity for DNA, and can bind RNA (PubMed:19123921).

> Gene Ontology [ TOP ]
Biological Process	GO:0000578 embryonic axis specification GO:0001558 regulation of cell growth GO:0001570 vasculogenesis GO:0001654 eye development GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001657 ureteric bud development GO:0001658 branching involved in ureteric bud morphogenesis GO:0001763 morphogenesis of a branching structure GO:0001822 kidney development GO:0001823 mesonephros development GO:0003002 regionalization GO:0003156 regulation of animal organ formation GO:0003338 metanephros morphogenesis GO:0007281 germ cell development GO:0007350 blastoderm segmentation GO:0007351 tripartite regional subdivision GO:0007354 zygotic determination of anterior/posterior axis, embryo GO:0007356 thorax and anterior abdomen determination GO:0007389 pattern specification process GO:0007423 sensory organ development GO:0007507 heart development GO:0007517 muscle organ development GO:0007530 sex determination GO:0007548 sex differentiation GO:0008380 RNA splicing GO:0008406 gonad development GO:0008584 male gonad development GO:0008585 female gonad development GO:0008595 anterior/posterior axis specification, embryo GO:0009798 axis specification GO:0009880 embryonic pattern specification GO:0009948 anterior/posterior axis specification GO:0009952 anterior/posterior pattern specification GO:0014074 response to purine-containing compound GO:0014706 striated muscle tissue development GO:0016049 cell growth GO:0022412 cellular process involved in reproduction in multicellular organism GO:0030198 extracellular matrix organization GO:0030308 negative regulation of cell growth GO:0030325 adrenal gland development GO:0030539 male genitalia development GO:0032835 glomerulus development GO:0032836 glomerular basement membrane development GO:0034698 response to gonadotropin GO:0035051 cardiocyte differentiation GO:0035239 tube morphogenesis GO:0035265 organ growth GO:0035270 endocrine system development GO:0035282 segmentation GO:0035502 metanephric part of ureteric bud development GO:0035801 adrenal cortex development GO:0035802 adrenal cortex formation GO:0035850 epithelial cell differentiation involved in kidney development GO:0042692 muscle cell differentiation GO:0042693 muscle cell fate commitment GO:0043010 camera-type eye development GO:0043062 extracellular structure organization GO:0045137 development of primary sexual characteristics GO:0045165 cell fate commitment GO:0045926 negative regulation of growth GO:0045927 positive regulation of growth GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046620 regulation of organ growth GO:0046622 positive regulation of organ growth GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0046683 response to organophosphorus GO:0048514 blood vessel morphogenesis GO:0048608 reproductive structure development GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048645 animal organ formation GO:0048732 gland development GO:0048738 cardiac muscle tissue development GO:0048754 branching morphogenesis of an epithelial tube GO:0048806 genitalia development GO:0051146 striated muscle cell differentiation GO:0051591 response to cAMP GO:0055007 cardiac muscle cell differentiation GO:0060039 pericardium development GO:0060231 mesenchymal to epithelial transition GO:0060419 heart growth GO:0060420 regulation of heart growth GO:0060421 positive regulation of heart growth GO:0060485 mesenchyme development GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0060539 diaphragm development GO:0060541 respiratory system development GO:0060562 epithelial tube morphogenesis GO:0060675 ureteric bud morphogenesis GO:0060911 cardiac cell fate commitment GO:0060923 cardiac muscle cell fate commitment GO:0060993 kidney morphogenesis GO:0061005 cell differentiation involved in kidney development GO:0061032 visceral serous pericardium development GO:0061138 morphogenesis of a branching epithelium GO:0061213 positive regulation of mesonephros development GO:0061217 regulation of mesonephros development GO:0061318 renal filtration cell differentiation GO:0061326 renal tubule development GO:0061333 renal tubule morphogenesis GO:0061437 renal system vasculature development GO:0061440 kidney vasculature development GO:0061448 connective tissue development GO:0061458 reproductive system development GO:0071320 cellular response to cAMP GO:0071371 cellular response to gonadotropin stimulus GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0072001 renal system development GO:0072006 nephron development GO:0072009 nephron epithelium development GO:0072010 glomerular epithelium development GO:0072012 glomerulus vasculature development GO:0072028 nephron morphogenesis GO:0072050 S-shaped body morphogenesis GO:0072073 kidney epithelium development GO:0072074 kidney mesenchyme development GO:0072075 metanephric mesenchyme development GO:0072078 nephron tubule morphogenesis GO:0072080 nephron tubule development GO:0072088 nephron epithelium morphogenesis GO:0072109 glomerular mesangium development GO:0072110 glomerular mesangial cell proliferation GO:0072111 cell proliferation involved in kidney development GO:0072112 glomerular visceral epithelial cell differentiation GO:0072124 regulation of glomerular mesangial cell proliferation GO:0072125 negative regulation of glomerular mesangial cell proliferation GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0072166 posterior mesonephric tubule development GO:0072171 mesonephric tubule morphogenesis GO:0072203 cell proliferation involved in metanephros development GO:0072207 metanephric epithelium development GO:0072210 metanephric nephron development GO:0072215 regulation of metanephros development GO:0072216 positive regulation of metanephros development GO:0072217 negative regulation of metanephros development GO:0072223 metanephric glomerular mesangium development GO:0072224 metanephric glomerulus development GO:0072239 metanephric glomerulus vasculature development GO:0072262 metanephric glomerular mesangial cell proliferation involved in metanephros development GO:0072273 metanephric nephron morphogenesis GO:0072284 metanephric S-shaped body morphogenesis GO:0072298 regulation of metanephric glomerulus development GO:0072299 negative regulation of metanephric glomerulus development GO:0072301 regulation of metanephric glomerular mesangial cell proliferation GO:0072302 negative regulation of metanephric glomerular mesangial cell proliferation GO:0072311 glomerular epithelial cell differentiation GO:0090183 regulation of kidney development GO:0090184 positive regulation of kidney development GO:0090185 negative regulation of kidney development GO:0090192 regulation of glomerulus development GO:0090194 negative regulation of glomerulus development GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1901722 regulation of cell proliferation involved in kidney development GO:1901723 negative regulation of cell proliferation involved in kidney development GO:2000018 regulation of male gonad development GO:2000020 positive regulation of male gonad development GO:2000027 regulation of organ morphogenesis GO:2000194 regulation of female gonad development GO:2000195 negative regulation of female gonad development GO:2000241 regulation of reproductive process GO:2000242 negative regulation of reproductive process GO:2000243 positive regulation of reproductive process GO:2001074 regulation of metanephric ureteric bud development GO:2001076 positive regulation of metanephric ureteric bud development
Molecular Function	GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0010385 double-stranded methylated DNA binding GO:0044729 hemi-methylated DNA-binding GO:0070742 C2H2 zinc finger domain binding
Cellular Component	GO:0016604 nuclear body GO:0016607 nuclear speck

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between WT1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between WT1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29358173	Pancreatic ductal adenocarcinoma	Promote immunity	We assessed WT1-specific immune responses via delayed-type hypersensitivity (DTH) to the WT1 peptide and a tetramer assay to detect WT1-specific cytotoxic T lymphocytes (WT1-CTL). These clinical effects were associated with the induction of WT1-specific immune responses.
29322496	Thymic carcinoma; Invasive Thymoma	Promote immunity (T/NK cell function); essential for immunotherapy	WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies. WT1 peptide vaccine immunotherapy may have antitumor potential against thymic malignancies.
16397021	Breast carcinoma	Promote immunity (T cell function); essential for immunotherapy	We have tested the working hypotheses that WT1 can be immunogenic in patients with breast cancer and can stimulate CTL of sufficient avidity to kill tumor cells. These results show that WT1-specific CTL can be expanded from the tumor-draining lymph nodes of breast cancer patients and that they can display peptide-specific effector function. This suggests that induction of autologous WT1-specific CTL may offer only limited tumor protection and that strategies that allow a high level of peptide/MHC complex presentation and/or improve CTL avidity may be required.
19389880	Acute Myeloid Leukemia	Promote immunity	This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations.
19351755	Leukemia	Promote immunity	We developed a novel Ad vector encoding a truncated version of WT1 (Ad-tWT1) lacking the highly conserved COOH terminus zinc finger domains and tested its ability to stimulate WT1-specific immune responses and antitumor immunity in two murine models of WT1-expressing tumors. In addition, vaccination of C57BL/6 mice with Ad-tWT1 generated WT1-specific cell-mediated and humoral immune responses and conferred protection against challenge with the leukemia cell line, mWT1-C1498. Moreover, in a tumor therapy model, Ad-tWT1 vaccination of TRAMP-C2 tumor-bearing mice significantly suppressed tumor growth.
23838315	Childhood acute lymphoblastic leukemia	Promote immunity (T cell function); essential for immunotherapy	Peripheral blood mononuclear cells were stimulated with autologous dendritic cells pulsed with complete peptide libraries of WT1, Survivin, MAGE-A3, and PRAME, antigens frequently expressed on ALL blasts. Antigen-specificity was observed in more than 50% of patients after the initial stimulation and increased to more than 90% after three stimulations as assessed in IFN-γ-enzyme-linked immunospot (ELISpot) and (51)Cr-release assays. This study supports the use of immunotherapy with adoptively transferred autologous tumor antigen-specific T cells to prevent relapse and improve the prognosis of patients with high-risk ALL.
22466705	Leukemia	Promote immunity (T cell function); essential for immunotherapy	After lentiviral transfer of a TCR specific for the Wilms tumor 1 (WT1) antigen, these TCR-edited cells expressed the new TCR at high levels, were easily expanded to near purity and were superior at specific antigen recognition compared to donor-matched, unedited TCR-transferred cells.
21540460	Chronic Lymphocytic Leukemia	Promote immunity (T cell function)	Donor-derived mature dendritic cells generated in vitro from CD14(+) monocytes were loaded with human leukocyte Ag-restricted peptides derived from PR1, WT1, and/or B-cell receptor-ABL and used to repetitively stimulate donor CD8(+) T cells in the presence of IL-2 and IL-7.
18676860	Leukemia	Promote immunity	The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. The Wilms' tumor antigen (WT1) is overexpressed in several human leukemias and thus considered as promising target for development of leukemia vaccine. Furthermore, priming of T cells with the WT1-126 HLA-A0201-restricted peptide in the presence of T(regs) strongly inhibited the induction of anti-WT1-126 CD8(+) CTL responses as evidenced by both very low cytotoxic activity and IFN-gamma production.
18502835	Leukemia	Promote immunity	The Wilms tumor antigen, WT1, is associated with several human cancers, including leukemia. We evaluated WT1 as an immunotherapeutic target using our proven DNA fusion vaccine design, p.DOM-peptide, encoding a minimal tumor-derived major histocompatibility complex (MHC) class I-binding epitope downstream of a foreign sequence of tetanus toxin.
20631300	Acute Myeloid Leukemia	Promote immunity	Two patients in partial remission after chemotherapy were brought into complete remission after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. Clinical responses were correlated with vaccine-associated increases in WT1-specific CD8+ T cell frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination.
16990779	leukemia	Promote immunity	Importantly, T cells stimulated with the new analogs crossreacted with the native WT1 peptide sequence and were able to kill HLA-matched chronic myeloid leukemia cell lines. In conclusion, analog heteroclitic WT1 peptides with increased immunogenicity can be synthesized and are potential cancer vaccine candidates.

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of WT1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of WT1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.24	0.417
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.538	0.296
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.017	0.97
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.335	0.545
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.575	0.671
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.037	0.981
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.181	0.839
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.475	0.723
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.889	0.534
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-1.164	0.223
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.488	0.247
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.657	0.132

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of WT1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WT1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WT1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WT1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WT1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of WT1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between WT1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	WT1
Name	Wilms tumor 1
Aliases	WIT-2; AWT1; GUD; EWS-WT1; NPHS4; WT33; Wilms tumor protein isoform Ex4a(+); Wilms tumor protein
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting WT1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse WT1